China Shineway Pharmaceutical Group Ltd (2877.HK) saw its stock price plummet by 5.24% during intraday trading on Friday, despite the company reporting strong financial results for the fiscal year and announcing a dividend payout.

According to the company's financial report, China Shineway Pharmaceutical Group achieved a net income of RMB 840 million for the fiscal year, with sales reaching RMB 3,780 million. The company maintained a robust gross margin of 75%, indicating strong profitability. Additionally, the pharmaceutical firm declared its first interim dividend for 2025 of RMB36 cents per share, which typically signals confidence in the company's financial health.

However, the stock's sharp decline suggests that investors may have had higher expectations or are concerned about other factors not immediately apparent in the financial results. Possible reasons for the sell-off could include worries about future growth prospects, industry-wide challenges, or broader market sentiment affecting pharmaceutical stocks. The disconnect between the company's solid financial performance and the stock's negative reaction highlights the complex nature of stock market dynamics, where positive news doesn't always translate to stock price appreciation.